文献速递妇科肿瘤

信迪利单抗联合安罗替尼治疗PD-L1阳性复发或转移性宫颈癌的疗效与安全性:一项多中心、单臂、前瞻性II期试验

Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1-Positive Recurrent or Metastatic Cervical Cancer: A Multicenter, Single-Arm, Prospective Phase II Trial.
PubMed 文献 · J Clin Oncol · 2022-02-22

该多中心单臂前瞻性II期试验纳入42例PD-L1阳性(CPS≥1)复发或转移性宫颈癌患者,接受信迪利单抗200 mg联合安罗替尼10 mg治疗,主要终点客观缓解率为54.8%(95%CI 38.7-70.2),中位无进展生存期9.4个月(95%CI 8.0-14.6),总生存期未达到,结论认为该方案二线及以上治疗有效且安全。

要点

  • 42例PD-L1阳性复发或转移性宫颈癌患者接受信迪利单抗联合安罗替尼治疗,客观缓解率为54.8%。
  • 39例可评估疗效患者中客观缓解率59.0%,疾病控制率94.9%,中位无进展生存期9.4个月。
  • 85.8%患者发生治疗相关不良事件,最常见为甲状腺功能减退(33.3%)、天冬氨酸氨基转移酶升高(21.4%)和高血压(19.0%)。

核心结论

  • 信迪利单抗联合安罗替尼作为既往化疗失败晚期宫颈癌患者的二线或后线治疗有效且安全。

研究设计与样本

  • 多中心、单臂、前瞻性II期试验,纳入42例PD-L1阳性(综合阳性评分≥1)复发或转移性宫颈癌患者。
  • 患者接受信迪利单抗200 mg第1天一次联合安罗替尼10 mg每日一次第1-14天,每3周重复。
  • 主要终点为研究者根据RECIST v1.1确认的客观缓解率,次要终点包括无进展生存期、总生存期和疾病控制率,并探索生物标志物。

主要发现

  • 42例患者客观缓解率为54.8%(95%CI 38.7-70.2)。
  • 39例可评估疗效患者客观缓解率为59.0%(95%CI 42.1-74.4),疾病控制率为94.9%(95%CI 82.7-99.4)。
  • 中位无进展生存期为9.4个月(95%CI 8.0-14.6),中位总生存期未达到。
  • 85.8%患者发生治疗相关不良事件,最常见为甲状腺功能减退(33.3%)、天冬氨酸氨基转移酶升高(21.4%)和高血压(19.0%)。
  • PIK3CA、PI3K-AKT信号通路或KMT2D改变的患者客观缓解率更高,而STK11和/或JAK2改变的患者无进展生存期显著缩短。

临床怎么用

  • 对于既往化疗失败的PD-L1阳性晚期宫颈癌患者,信迪利单抗联合安罗替尼可作为二线或后线治疗选择。

局限性

  • 单臂设计未设对照组。
  • 样本量较小(42例)。
  • 总生存期数据未成熟(中位总生存期未达到)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: No combined immunotherapy and antiangiogenic therapy have been investigated in exclusively programmed death-ligand 1 (PD-L1)-positive advanced cervical cancer (CA). We investigated the efficacy and safety of sintilimab plus anlotinib as second-line or later therapy for PD-L1-positive recurrent or metastatic (R/M) CA. PATIENTS AND METHODS: Patients with PD-L1-positive (Combined Positive Score ≥ 1) R/M CA who progressed after at least one prior systemic chemotherapeutic regimen or could not tolerate chemotherapy were eligible for the phase II trial. The patients received 200 mg sintilimab once on day 1 and 10 mg anlotinib once daily on days 1-14 every 3 weeks. The primary end point was investigator-confirmed objective response rate (ORR) per RECIST v1.1. Secondary end points included progression-free survival (PFS), overall survival, and disease control rate. Biomarkers were explored. RESULTS: Forty-two patients were enrolled. The ORR was 54.8% (95% CI, 38.7 to 70.2). In 39 efficacy-evaluable patients, the ORR was 59.0% (95% CI, 42.1 to 74.4); the disease control rate was 94.9% (95% CI, 82.7 to 99.4). The median PFS was 9.4 months (95% CI, 8.0 to 14.6). The median overall survival was not reached. Furthermore, 85.8% of the patients experienced treatment-related adverse events. The most frequent treatment-related adverse events were hypothyroidism (33.3%), elevated aspartate aminotransferase levels (21.4%), and hypertension (19.0%). Patients with altered PIK3CA, PI3K-AKT signaling, or KMT2D had a higher ORR, whereas those with altered STK11 and/or JAK2 had a significantly shorter PFS. CONCLUSION: Sintilimab plus anlotinib as second-line or later therapy is efficacious and safe for patients with advanced CA who have failed prior chemotherapy.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Xu Q, Wang J, Sun Y, et al. Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1-Positive Recurrent or Metastatic Cervical Cancer: A Multicenter, Single-Arm, Prospective Phase II Trial. J Clin Oncol. 2022. PMID: 35192397. doi:10.1200/JCO.21.02091

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。